Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Cash Flow (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Net Cash Flow for 16 consecutive years, with -$396541.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 1183.76% year-over-year to -$396541.0, compared with a TTM value of -$417862.0 through Sep 2025, up 37.78%, and an annual FY2024 reading of -$764365.0, down 19.8% over the prior year.
  • Net Cash Flow was -$396541.0 for Q3 2025 at China Pharma Holdings, down from $248713.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $4.4 million in Q4 2021 and bottomed at -$1.4 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$20401.8, with a median of -$65874.0 recorded in 2024.
  • The sharpest move saw Net Cash Flow skyrocketed 9298.63% in 2023, then plummeted 1835.09% in 2024.
  • Year by year, Net Cash Flow stood at $4.4 million in 2021, then crashed by 101.36% to -$60201.0 in 2022, then skyrocketed by 105.86% to $3528.0 in 2023, then tumbled by 1835.09% to -$61214.0 in 2024, then crashed by 547.79% to -$396541.0 in 2025.
  • Business Quant data shows Net Cash Flow for CPHI at -$396541.0 in Q3 2025, $248713.0 in Q2 2025, and -$208820.0 in Q1 2025.